{"id":120,"date":"2009-05-07T12:41:27","date_gmt":"2009-05-07T17:41:27","guid":{"rendered":"https:\/\/www.bowdish.ca\/lab\/?p=120"},"modified":"2009-05-07T12:42:30","modified_gmt":"2009-05-07T17:42:30","slug":"breaking-news-inimex-pharmaceuticals-begins-first-clinical-study-of-an-innate-defense-regulator","status":"publish","type":"post","link":"https:\/\/www.bowdish.ca\/lab\/2009\/05\/07\/breaking-news-inimex-pharmaceuticals-begins-first-clinical-study-of-an-innate-defense-regulator\/","title":{"rendered":"Breaking News: Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator"},"content":{"rendered":"<p>During the course of Dr. Bowdish&#8217;s PhD she discovered that host defence peptides (formerly known as <a href=\"http:\/\/en.wikipedia.org\/wiki\/Antimicrobial_peptides\">antimicrobial peptides<\/a>) were not actually bactericidal under physiological conditions. Instead they worked by interacting with the leukocytes as &#8220;immunomodulators&#8221; altering cytokine responses and chemotaxis and altering the leukocyte&#8217;s pro-inflammatory response. This work was the basis of a patent which resulted in the creation of <a href=\"http:\/\/www.inimexpharma.com\/\">Inimex Pharmaceuticals<\/a>. Recently Inimex has announced that they have successfully passed Phase I clinical trial for their IDR (Immune Defence Regulator), a new class of anti-infective drugs. Read the press release <a href=\"http:\/\/www.inimexpharma.com\/documents\/PressRelease_FirstClinicalStudy_Apr2709_001.pdf#2009\">here<\/a>.<\/p>\n<p>The Bowdish lab has an ongoing interest in developing novel anti-infective agents.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>During the course of Dr. Bowdish&#8217;s PhD she discovered that host defence peptides (formerly known as antimicrobial peptides) were not actually bactericidal under physiological conditions. Instead they worked by interacting with the leukocytes as &#8220;immunomodulators&#8221; altering cytokine responses and chemotaxis &hellip; <a href=\"https:\/\/www.bowdish.ca\/lab\/2009\/05\/07\/breaking-news-inimex-pharmaceuticals-begins-first-clinical-study-of-an-innate-defense-regulator\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[34,32],"class_list":["post-120","post","type-post","status-publish","format-standard","hentry","category-news","tag-drug-discovery","tag-immunomodulator"],"_links":{"self":[{"href":"https:\/\/www.bowdish.ca\/lab\/wp-json\/wp\/v2\/posts\/120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bowdish.ca\/lab\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bowdish.ca\/lab\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bowdish.ca\/lab\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bowdish.ca\/lab\/wp-json\/wp\/v2\/comments?post=120"}],"version-history":[{"count":3,"href":"https:\/\/www.bowdish.ca\/lab\/wp-json\/wp\/v2\/posts\/120\/revisions"}],"predecessor-version":[{"id":123,"href":"https:\/\/www.bowdish.ca\/lab\/wp-json\/wp\/v2\/posts\/120\/revisions\/123"}],"wp:attachment":[{"href":"https:\/\/www.bowdish.ca\/lab\/wp-json\/wp\/v2\/media?parent=120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bowdish.ca\/lab\/wp-json\/wp\/v2\/categories?post=120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bowdish.ca\/lab\/wp-json\/wp\/v2\/tags?post=120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}